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Body fat changes and metabolic abnormalities such as hyperlipidaemia and diabetes have been
increasingly reported following the successful introduction of highly active antiretroviral therapy
(HAART). These side effects were attributed initially to the use of protease inhibitors (PIs). As a conse-
quence, a series of trials were conducted where patients with well-controlled HIV viraemia either con-
tinued on PIs or were switched to a simplified maintenance therapy (SMT) without PIs. Evidence from
these trials is still insufficient to show that switching from PIs to either abacavir, nevirapine or efavir-
enz is safe. However, patients with suboptimal pre-HAART treatment are at increased risk of virological
failure if switched to an SMT. Patients switched from PI regimens tend to stay longer on an SMT and
those switched to abacavir show a reduction in total cholesterol, but there is no evidence of any
additional benefit from non-PI-based SMT. There is a clear need for a better understanding of HAART-
related lipodystrophy and metabolic toxicity, and pharmacogenetic tests to identify those patients
most at risk. The advent of simpler formulations for all drug classes, and new PIs with less metabolic
toxicity, is likely to reshape completely the role of SMT.
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Introduction
Highly active antiretroviral therapy (HAART) has led to a dra-
matic improvement in the survival of HIV-infected individuals
in resource-rich countries. In these countries, issues of chronic
disease management and long-term drug toxicity have become
the central focus of clinicians caring for those with HIV. Five
years ago, changes in body fat and lipid metabolism, now com-
monly known as lipodystrophy, were first described in patients
receiving protease inhibitors (PIs).1 These changes are character-
ized by facial or peripheral lipoatrophy and central lipohyper-
trophy, metabolic disorders with increases in cholesterol and
triglycerides, increased lactate and blood glucose and increased
insulin resistance.
An association between stavudine and lipoatrophy has been
found in several clinical trials and in one well-designed prospec-
tive cohort study.2,3 PI-based regimens have been associated with
increased blood lipids in cross-sectional studies.4 However,
because of study-design limitations (cross-sectional or retrospec-
tive cohort studies), inconsistencies in the definition of lipodystro-
phy, and the number of possible antiretroviral drugs and drug
combinations, so far it has been impossible to give a more defini-
tive hierarchy of responsible drugs or drug classes in a causal path-
way leading to lipodystrophy.
PIs may promote lipodystrophy when they bind to the cataly-
tic site used by HIV protease, by inhibiting lipid and adipocyte
regulatory proteins that also partially use this site.5 In addition,
in vitro studies have shown that PIs can inhibit the differen-
tiation of premature adipocytes, which may in turn lead to
decreased storage of triglycerides, insulin resistance and apopto-
sis. PIs have been associated with elevated blood lipids and insu-
lin resistance.6 For example, ritonavir use for 2 weeks in
volunteers without HIV led to increases in cholesterol and trigly-
cerides.6 There is increasing evidence that nucleoside analogue
reverse transcriptase inhibitors (NRTIs) lead to mitochondrial
toxicity and this may be associated with some types of lipo-
atrophy. NRTIs may inhibit adipogenesis and stimulate lipolysis;
and in vitro studies show that they may have synergistic effects
with PIs. 6 In addition, NRTI use is associated with a variety of
other side effects of mitochondrial toxicity, such as hyperlact-
aemia, liver steatosis, myopathy and peripheral neuropathy.
Rationale of PI-sparing simplified maintenance
therapy (SMT)
Concerns about the long-term risk of cardiovascular disease
from these metabolic disorders have been confirmed by the DAD
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study.7 These concerns led to a series of clinical trials where
patients with well-controlled HIV viraemia were switched to
non-PI-based regimens. The goal of these trials was to reduce or
reverse the metabolic disorders attributed to PIs and to improve
the convenience of and adherence to antiretroviral therapy—by
avoiding PI regimens with a high pill burden and restrictive diet-
ary requirements. A first generation of trials looked at whether
switching from PI-based therapy to a non-PI SMT would main-
tain optimal viral suppression and reduce body fat changes and
blood abnormalities.8 What are the risks and benefits of PI-
sparing SMT and what might be the role of SMT in the future?
Effect of SMT on HIV-1 viral suppression
In a meta-analysis of randomized controlled trials,8 we identified
nine trials that compared continued PIs versus a switch to an
SMT, using either abacavir (three trials), efavirenz (three trials)
or nevirapine (two trials). In an additional trial, individuals were
randomly switched from PIs to either efavirenz or nevirapine.
Three trials were conducted in patients with lipodystrophy at
baseline. The analysis included 833 individuals treated with an
SMT and 616 individuals treated with continued PI-based
therapy. Compared with continued PIs, the risk ratio for virolo-
gical failure in abacavir trials was 2.56 (95% CI 1.17–5.64), in
efavirenz trials 0.83 (95% CI 0.36–1.91) and in nevirapine trials
0.54 (95% CI 0.29–1.02). In a post-hoc subgroup analysis of
trials with abacavir, we were unable to show or rule out that the
increased risk of virological failure under SMT with abacavir
was associated with prior suboptimal mono or dual NRTI
therapy. In two abacavir trials with information on baseline
resistance testing, there was no clear pattern to suggest that
patients with virological failure had genotypic resistance at the
time of switching. No difference in the mean change in CD4
cells was found for SMT with any of the three drugs compared
with continued PIs (–17 CD4 cells/mm3, 95% CI 46 to 11).
However, treatment discontinuation for any reason other than
drug failure was much less likely with SMT (risk ratio 0.61;
95% CI 0.48–0.77). Convenience and a better tolerance of SMT
were the main reasons for the lower discontinuation rate.
These findings are in line with a trial by Martinez et al.,9
where all patients on PIs were switched to either abacavir, efa-
virenz or nevirapine. There was no difference between the three
groups in the rate of progression to virological failure, AIDS or
death. In a post-hoc subgroup analysis, the hazard rate for viro-
logical failure in patients with prior suboptimal mono or dual
NRTI therapy was 3.76 (95% CI 1.53–9.23), with the highest
failure rate in the abacavir group.
The available evidence from clinical trials is insufficient to
show that switching to SMT is safe, but there are indications of
an increased risk of virological failure for patients with prior
suboptimal NRTI therapy. This risk seems to be highest for
patients on SMT with abacavir. For this reason, a switch to aba-
cavir should be reserved for patients with a known drug history
who have not undergone prior mono or dual NRTI therapy. Pre-
liminary data from the Eurosida cohort suggest a higher risk of
virological failure in patients with prior suboptimal NRTI
therapy taking abacavir or nevirapine compared with those
taking efavirenz: patients taking abacavir are at higher risk than
those taking nevirapine. However, in pre-HAART naive patients,
there was no difference among the three drugs.10
Effect of SMT on metabolic parameters
In our meta-analysis, the difference in absolute mean cholesterol
for SMT compared with continued PIs was 0.15 mmol/L (95%
CI 0.40 to 0.09), suggesting a trend towards lower cholesterol
levels in patients taking SMT. In planned subgroup analyses,
the difference in cholesterol for SMT with abacavir was
0.51 mmol/L (95% CI 0.70 to 0.33), with efavirenz
0.22 mmol/L (95% CI 0 to 0.43) and with nevirapine
0.19 mmol/L (95% CI 0.48 to 0.09) compared with continued
PIs. The difference in absolute mean triglycerides for SMT com-
pared with PIs was 0.38 mmol/L (95% CI 0.57 to 0.18).
Trials using different switch protocols have confirmed a mod-
erate cholesterol reduction when switching from PIs to abaca-
vir.9,11 The reduction in cholesterol seen with abacavir is
clinically important and is particularly relevant for HIV-infected
patients with established coronary heart disease or multiple
cardiovascular risk factors.
Effect of SMT on lipodystrophy
Several trials have used dual X-ray absorptiometry (DEXA) to
compare changes in peripheral and central body fat distribution
between continued PI-based regimens and a switch to an SMT.
In two trials, no difference in fat distribution was seen after
switching to nevirapine or efavirenz.12,13 In a third trial, a
decrease in intra-abdominal and a slight decrease in brachial fat
was found with a switch to efavirenz when compared with con-
tinued PIs.14 Two additional trials investigated switches from PIs
to a combination of abacavir, nevirapine, adefovir and hydroxy-
urea11 or to abacavir.15 Patients switching showed a decrease in
limb, subcutaneous abdominal and intra-abdominal fat mass in
one trial,11 and a moderate increase in leg and arm fat in the
other trial.15 Given the different protocols, open trial design
possibly without blinded outcome assessment of DEXA, and the
short follow-up time, these trials do not provide convincing evi-
dence that switching from PIs to SMT is associated with a clini-
cally relevant improvement in the redistribution of body fat. And
two trials switching antiretroviral drugs because of lipodystrophy
failed to show any improvement in body fat redistribution that
was considered relevant by patients.14,16
The future of SMT
Continued advances in therapy over the last decade have justi-
fied the initial optimism for second- and third-generation anti-
retroviral drugs. Recent potent PIs, such as boosted lopinavir or
saquinavir, are effective even against medium-resistant isolates.
Ever more potent drugs are desirable, but the potency of drugs is
already fairly high in patients naive to therapy, especially when
adherence is optimal. Therefore, the focus of antiretroviral drug
development may shift towards drugs with fewer side effects
and towards drugs that are easier to take. With the advent of
additional antiretroviral drugs and drug classes, individualized
antiretroviral therapy to optimize tolerance and adherence should
become standard. The introduction of new drug compounds and
boosted PI regimens should allow PIs to be used with a lower
pill burden in once-daily regimens and with lower risk of meta-
bolic toxicity. Therefore, convenience and metabolic toxicity
will be less of an issue in the decision to switch PIs in the future.
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As yet, there is little evidence from clinical trials on the efficacy
and safety of PI and non-PI once-daily regimens. Further clinical
trials are needed to address this question, and in particular in
patients with known adherence problems. Significant progress
has been made in understanding the pathogenesis of lipodys-
trophy and its associated metabolic disorders. However, basic
research, pharmacogenetics and long-term prospective cohort
studies are needed to understand better the role of different
drugs and drug classes in the development of lipodystrophy and
to define better those individuals most at risk. Given the potency
of some boosted PIs and the potential to identify patients with a
genetic predisposition towards lipodystrophy, PI monotherapy
may be a valid option in the future for some patients. Such
potent monotherapies could have lower toxicity—meanwhile
keeping other therapy options in reserve in case of drug resist-
ance. The spread of resistant viral strains will re-emphasize the
importance of very potent simple regimens and of the need to
think carefully about future therapy options for our patients.
Conclusions
The decision to switch patients with well-controlled HIV-1
viraemia from a PI to a non-PI regimen should be individualized
based on issues of tolerance, risk for cardiovascular disease and
convenience. Future therapy options should always be borne in
mind when switching therapy. The introduction of new PIs with
less metabolic toxicity and a low pill burden will further reduce
the need to switch PIs. Current evidence suggests that switching
from PIs to an SMT may be safe, more convenient and may
reduce future therapy changes. However, switching from PIs to
abacavir should be reserved for patients with a known drug his-
tory and no prior suboptimal mono or dual NRTI therapy; other-
wise the risk of viral rebound is increased. Switching to abacavir
leads to a clinically relevant reduction of hypercholesterolaemia
and can be considered in patients at substantial risk of coronary
heart disease (e.g. 20% 10 year risk or higher of a coronary
event). For patients with well-controlled HIV viraemia, there is
little evidence of any further advantage that would justify a
switch from a PI to a non-PI regimen.
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